Synergistic Antitumor Activity between HER2 Antibody-Drug Conjugate and Chemotherapy for Treating Advanced Colorectal Cancer

Researchers proposed the therapeutic efficacy and molecular mechanism underlying RC48, a FDA-approved anti human epidermal growth factor receptor 2 (HER2) antibody conjugate via a cleavable linker to the microtubule inhibitor monomethyl auristatin E, either alone or in combination with gemcitabine in various models of HER2-positive advanced colorectal cancer.